Limit opioid prescriptions to just seven days, say drugmakers

28 September 2017

The US pharmaceutical industry has signaled its support for severe limitations on the length of opioid prescriptions, saying it would be happy if the current 30-day maximum was reduced to just seven days.

The industry’s trade federation, Pharmaceutical Research and Manufacturers of America (PhRMA), caveated that prescribers should be able to deviate from any mandate, for example for cancer-related pain or hospice care.

The move follows recent announcements from insurance giants CVS and Express Scripts that they would impose a seven-day limit on prescriptions, also with some exceptions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK